Dr Shahr Bano, Dr Fatima Khosa, Dr Jawaria Qureshi
Introduction: Approximately 170 million people worldwide are chronically infected by hepatitis C virus (HCV), which can result in progressive hepatic injury and fibrosis, culminating in cirrhosis and end-stage liver disease. Objectives: The main objective of the study is to find the concentration and dose of Ribavirin in treatment of chronic hepatitis-C infected patients. Material and methods: This cross sectional study was conducted in Rawalpindi Medical University and Shalamar Hospital Lahore during 2019. The data was collected from 100 patients of chronic Hepatitis-C. The primary outcome was to evaluate the efficacy of the regimen used. Results: The data was collected from 100 hepatitis patients. The mean age was 36.5 + 10.1 years and BMI of the patients was 21.7 ± 2.7 (kg/m2). The mean duration of HIV was 38 ± 43.8 months. There were non-significant relationship present in diseased group treated with different therapies like interferon and glutathione as as p<0.05. The level of micronutrients become decreases in diseased group. Conclusion: It is concluded that there are no alternatives to RBV for the treatment of HCV infection, and therefore, maintaining patients on their indicated dose and length of therapy is crucial if the goal of a high rate of SVR is to be achieved.